Sección Hepatología, Hospital Italiano de Buenos Aires-Argentina, Ciudad de Buenos Aires, Argentina.
Ann Hepatol. 2010;9 Suppl:34-8.
The current optimal approach to detecting hepatitis C virus (HCV) infection involves screening people for risk factors and only testing selected individuals at risk. Blood transfusion from infectious donors, unsafe therapeutic injection practices, and illegal intravenous drug use have been the predominant modes of transmission of HCV infection. Virological markers that are currently used for the clinical management of patients with hepatitis C include serologic assays (ELISA or immunoblot assays), which detect specific antibodies (IgG) to HCV, and virological assays, which detect serum HCV RNA, by highly sensitive qualitative and quantitative techniques. The applicability of these tests is for the diagnoses and monitoring of the treatment but they have no role in the assessment of disease severity or prognosis. Patients diagnosed with HCV infection must be educated in order to avoid the spread of the disease to other people.
目前检测丙型肝炎病毒（HCV）感染的最佳方法是对有风险因素的人群进行筛查，仅对有风险的特定个体进行检测。血液输注来自感染源、不安全的治疗性注射实践和非法静脉注射药物是 HCV 感染的主要传播途径。目前用于丙型肝炎患者临床管理的病毒学标志物包括血清学检测（ELISA 或免疫印迹检测），可检测针对 HCV 的特异性抗体（IgG），以及病毒学检测，可通过高度敏感的定性和定量技术检测血清 HCV RNA。这些检测方法可用于诊断和监测治疗，但不能用于评估疾病严重程度或预后。必须对诊断为 HCV 感染的患者进行教育，以避免将疾病传播给其他人。
